<DOC>
	<DOC>NCT01389466</DOC>
	<brief_summary>This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study. The investigator evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers</brief_title>
	<detailed_description>MG1109 is purified, inactivated influenza viral antigen.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Healthy adults who are available for followup during the study Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine Subjects with immune system disorder including immune deficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Avian influenza</keyword>
</DOC>